Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Summary
- Dr. Mithun Shah is an oncologist in Rochester, MN, specializing in Hematologic Oncology. He completed his residency in Internal Medicine at Penn State Milton S Hershey Medical Center from 2010 to 2013. Subsequently, he undertook a fellowship in Hematology and Medical Oncology at Mayo Clinic College of Medicine and Science between 2013 and 2017. Dr. Shah's clinical expertise includes conducting bone marrow biopsies and aspirations. Among his publications, prominent ones include research articles published in reputed journals such as JAMA Oncology, Blood Advances, British Journal of Haematology, Haematologica, and Bone Marrow Transplantation.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2017
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2010 - 2013
B. J. Medical College AhmedabadClass of 2002
Certifications & Licensure
MN State Medical License 2013 - 2025
PA State Medical License 2010 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 39 citationsEpigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaZainul Hasanali, Bikramajit Singh Saroya, August Stuart, Sara Shimko, Juanita J. Evans
Science Translational Medicine. 2015-06-24 - 7 citationsBRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.Aldo A Acosta-Medina, Paul G Kemps, Timo C E Zondag, Jithma P Abeykoon, Jelske Forma-Borst
Blood. 2023-11-02 - 10 citationsVenetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough
American Journal of Hematology. 2024-02-01
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Abstracts/Posters
- Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be BeneficialMithun Vinod Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical Features and Outcomes of Unifocal Adult Langerhans Cell HistiocytosisMithun Vinod Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell TransplantationMithun Vinod Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
FISH Testing Helps Detect Unseen Cancer CellsJanuary 22nd, 2024
Professional Memberships
- Associate
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
